FDA chief to depart after Trump signed off on ousting him
FDA Chief to Depart After Trump Signed Off on Ousting
FDA chief to depart after Trump – Marty Makary, the Food and Drug Administration’s head, is set to exit the Trump administration, according to three individuals who are well-informed about the situation. The decision was finalized following President Donald Trump’s approval of a plan to remove Makary last week. This marks another shift in the leadership of the US Health and Human Services Department, which has already seen vacancies in key positions such as the Centers for Disease Control and Prevention (CDC) director and the surgeon general. Makary’s resignation will require Trump to appoint a new permanent leader for the FDA, a process that depends on Senate confirmation.
The FDA chief faced relentless pressure from within the Trump administration, including from factions that were frustrated with the agency’s internal disputes and inconsistent policies. His resistance to approving the sale of flavored e-cigarettes became a focal point of this discontent. The issue sparked direct confrontation between Trump and Makary, with the president reportedly expressing frustration over the commissioner’s stance. This tension, combined with external pressures from groups like the pharmaceutical industry and anti-abortion advocates, ultimately led to his departure.
Trump is expected to name Kyle Diamantas, a deputy commissioner who leads the agency’s food program, as the acting FDA chief. The president confirmed the move in a post on Truth Social, stating that Makary had been removed from his position. Diamantas’s appointment signals a strategic realignment within the FDA, with the administration aiming to streamline decision-making and strengthen ties with key constituencies. However, Makary’s exit also creates an additional challenge for the HHS department, which must now navigate the confirmation process for a new permanent leader amid a busy political calendar.
Despite Makary’s efforts to retain Trump’s favor, the president’s faction within the White House and Health and Human Services (HHS) had grown increasingly impatient. In recent days, the pressure to replace him intensified, driven by officials who viewed the FDA’s leadership as a source of dysfunction. Makary, a surgeon and author, had previously pledged to expedite FDA decisions on drugs, devices, and vaccines after his March 2025 confirmation. Yet, over the past year, his tenure has been marred by controversy, particularly in the areas of tobacco regulation and the approval of e-cigarette flavors.
One recent incident that reignited debates about Makary’s role was his reluctance to endorse the sale of fruit-flavored e-cigarettes. This decision, which conflicted with the administration’s broader strategy to promote vaping as a tool for smoking cessation, led to direct intervention from Trump. Two individuals familiar with the situation described how the president became visibly upset with Makary’s stance, prompting a swift reversal in FDA policy. This reversal, however, did not fully satisfy the administration’s allies, who had long viewed flavored e-cigarettes as a gateway to increased youth smoking.
Alongside Makary’s ouster, White House and HHS officials are considering a major restructuring of the FDA’s senior staff. This move reflects a desire to eliminate internal conflicts and ensure alignment with the administration’s priorities. The FDA’s leadership has been a battleground for competing interests, with pharmaceutical companies and anti-abortion groups each vying for influence. Susan B. Anthony Pro-Life America’s president, Marjorie Dannenfelser, played a pivotal role in pushing for changes to FDA regulations, specifically targeting the mailing of mifepristone, the abortion pill. Her advocacy highlighted the growing divide between the FDA’s regulatory approach and the administration’s conservative agenda.
“He doesn’t want to approve youth-appealing flavors, but has been forced to by the powers that be,” a source close to Makary’s departure said. This quote underscores the tension between Makary’s personal convictions and the political pressures he faced. While the FDA’s reversal on flavored e-cigarettes was a compromise, it left Makary’s allies questioning the extent of his autonomy. The commissioner had sought to reassure Trump of his loyalty, telling associates that the president still trusted him. However, the sudden announcement of his resignation came as a surprise, sparking internal speculation about the motives behind the move.
Some Trump aides initially hesitated to act, fearing that removing another senior health official might alienate the administration’s “Make America Healthy Again” base. Critics argued that such a move could be perceived as a political misstep, especially as the midterms approach. Others, however, saw the departure as a necessary step to restore order and align the FDA with the administration’s goals. The restructuring of the agency’s leadership is part of this broader effort, with officials aiming to consolidate power and reduce bureaucratic friction. This shift also positions Diamantas to take a more assertive role in shaping FDA policies, particularly in food and drug regulation.
Makary’s resignation occurs just one day before he was scheduled to testify about the FDA’s proposed budget before the Senate Appropriations Committee. The timing of his exit has raised questions about the administration’s plans to reshape the agency’s future. Politico was the first to report his resignation, setting off a wave of analysis about the implications of the decision. With Makary’s departure, the FDA now enters a new phase of leadership, one that may prioritize speed and political alignment over independent scientific judgment.
The controversy surrounding Makary’s tenure has also highlighted the FDA’s role as a battleground for ideological battles. His resistance to certain regulations, such as those allowing mail-order access to mifepristone, has drawn sharp criticism from conservative groups. Meanwhile, pharmaceutical companies have expressed frustration with his management of the drug approval process, which they believe has slowed progress on key innovations. These competing pressures have created a volatile environment within the FDA, where decisions are often influenced by external agendas rather than internal consensus.
As the administration moves forward, the focus will shift to filling the vacant FDA commissioner role and ensuring that the new leader can navigate the complex landscape of health policy. The Senate confirmation process will be a critical test for the next appointee, with lawmakers expected to scrutinize their alignment with the Trump administration’s priorities. Meanwhile, the FDA’s restructuring efforts may lead to significant changes in how the agency operates, potentially reshaping its approach to regulating tobacco, drugs, and e-cigarettes in the months ahead.
Background on Makary’s Leadership
Marty Makary, a prominent surgeon and author, took over as FDA commissioner in March 2025 with a mandate to modernize the agency’s operations. His tenure was marked by ambitious goals to accelerate decision-making and streamline regulatory processes. However, these efforts were frequently met with resistance from within the agency, where differing opinions on issues such as tobacco regulation and e-cigarette policies created a climate of uncertainty. The constant turnover among senior officials further complicated the FDA’s ability to maintain a cohesive strategy, with Trump’s team seeking greater control over its direction.
Makary’s approach to flavored e-cigarettes became a lightning rod for criticism. While the FDA had initially approved the sale of these products, Makary’s push to limit their availability to protect young smokers led to a direct clash with the administration. His stance was seen as a hurdle to the broader policy of promoting vaping as a healthier alternative to traditional cigarettes. The episode not only strained his relationship with Trump but also exposed the fragility of his position within the HHS department. As the administration grew more assertive, Makary’s influence waned, culminating in his unexpected resignation.
The decision to remove Makary was not made lightly, but it reflects the administration’s strategy to consolidate control over key regulatory agencies. With the midterms approaching, Trump’s team is likely prioritizing appointments that can quickly implement their agenda without facing prolonged legislative delays. Diamantas, who has been a steady hand in the FDA’s food program, is well-positioned to take on this role. His experience and alignment with the administration’s priorities make him a logical choice for acting commissioner, though his long-term effectiveness will depend on his ability to manage the agency’s diverse interests.
As the FDA prepares for a new chapter, the agency’s future will be shaped by the balance between scientific rigor and political influence. Makary’s departure underscores the challenges of maintaining independence in a government where regulatory decisions are often tied to partisan goals. The agency’s ability to adapt to these pressures will be crucial in determining its role in the coming months, particularly as it navigates the complexities of drug approvals, tobacco regulations, and abortion access policies. For now, the focus remains on securing a new leader and stabilizing the FDA’s leadership structure under the Trump administration.
